George Clinical adds Philippines office to APAC lineup

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Derek Brumby)
(Image: Getty/Derek Brumby)

Related tags: George Clinical, Philippines, Asia pacific, Clinical trials, Clinical research

Headquartered in the Asia-Pacific, George Clinical deepens its footprint in the region with a new office in Manila, Philippines.

In an aim to collaborate, the global clinical research organization (CRO) opened another office in the Asia-Pacific (APAC). With its base in Australia, George Clinical has facilities in China, India, Hong Kong, South Korea, Taiwain, Malaysia, the UK, and the US. However, it provides services outside of those countries and has previously provided services directly to the Philippines.  

George Clinical opened this office in an aim to formalize the company’s collaborations within the area. According to the CRO, the Philippines was chosen strategically as it is not only a strong part of the region’s clinical trial landscape, but it has a large population of treatment naïve patients.

Additionally, it will enable the company to increase its investigational networks that may enhance study quality, performance, and efficiency.

The company explained in a statement that the Philippines has a strong track record in its conduct during trials for infectious diseases, oncology, metabolic disorders, respiratory and cardiovascular trials, which corresponds with the studies George Clinical intends to focus on in the country.  

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars